PHAR vs FOLD

For growth investors, Pharming Group N.

V. (PHAR) is the stronger pick with 26. 9% revenue growth year-over-year, versus 20. 0% for Amicus Therapeutics, Inc. (FOLD). Pharming Group N. V. (PHAR) offers the better valuation at 300. 0x trailing P/E (59. 2x forward), making it the more compelling value choice. Analysts rate Pharming Group N. V. (PHAR) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Amicus Therapeutics, Inc.

is actually cheaper at 40. 6x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Amicus Therapeutics, Inc.

(FOLD) delivered a total return of +48. 6%, compared to -9. 1% for Pharming Group N. V. (PHAR). Over 10 years, the gap is even starker: FOLD returned +119. 2% versus PHAR's -28. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Amicus Therapeutics, Inc.

(FOLD) is the lower-risk stock at 0. 63β versus Pharming Group N. V. 's 1. 22β — meaning PHAR is approximately 94% more volatile than FOLD relative to the S&P 500. On balance sheet safety, Pharming Group N. V. (PHAR) carries a lower debt/equity ratio of 42% versus 176% for Amicus Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Pharming Group N.

V. (PHAR) is pulling ahead at 26. 9% versus 20. 0% for Amicus Therapeutics, Inc. (FOLD). On earnings-per-share growth, the picture is similar: Pharming Group N. V. grew EPS 123. 5% year-over-year, compared to 51. 2% for Amicus Therapeutics, Inc.. Over a 3-year CAGR, FOLD leads at 24. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Pharming Group N.

V. (PHAR) is the more profitable company, earning 0. 8% net margin versus -4. 3% for Amicus Therapeutics, Inc. — meaning it keeps 0. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: FOLD leads at 5. 4% versus 5. 1% for PHAR. At the gross margin level — before operating expenses — PHAR leads at 87. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Amicus Therapeutics, Inc.

(FOLD) trades at 40. 6x forward P/E versus 59. 2x for Pharming Group N. V. — 18. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PHAR: 222. 3% to $38. 67.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Amicus Therapeutics, Inc.

(FOLD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 63), +119. 2% 10Y return). Both have compounded well over 10 years (FOLD: +119. 2%, PHAR: -28. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.